Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Nelson Hayes

Showing results (121-130 of 161) with videos related to

Pageof 17
Sort By:
Antimicrobial Agents and Chemotherapy|January 29, 2014
Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirinEisuke Murakami, Michio Imamura, C Nelson Hayes, et al.
The Journal of Infectious Diseases|February 28, 2022
Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAILYosuke Suehiro, Masataka Tsuge, Mio Kurihara, et al.
Journal of Hepatology|December 15, 2010
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric miceEiji Ohara, Nobuhiko Hiraga, Michio Imamura, et al.
Antiviral Therapy|June 2, 2018
Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot studyYumiko Tatsukawa, Masataka Tsuge, Yoshiiku Kawakami, et al.
Antiviral Therapy|January 12, 2019
Correction: Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot studyYumiko Tatsukawa, Masataka Tsuge, Yoshiiku Kawakami, et al.
Biochemical and Biophysical Research Communications|October 22, 2013
A novel TK-NOG based humanized mouse model for the study of HBV and HCV infectionsKeiichi Kosaka, Nobuhiko Hiraga, Michio Imamura, et al.
Journal of Gastroenterology|March 5, 2016
Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infectionMasataka Tsuge, Nobuhiko Hiraga, Takuro Uchida, et al.
Journal of Gastroenterology and Hepatology|December 20, 2021
Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver diseaseYutaro Ogawa, Takashi Nakahara, Masafumi Ono, et al.
Journal of Gastroenterology|September 16, 2016
Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis CReona Morio, Michio Imamura, Yoshiiku Kawakami, et al.
Hepatology (Baltimore, Md.)|March 10, 2023
HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric miceTakuro Uchida, Michio Imamura, C Nelson Hayes, et al.
Pageof 17

Showing results (121-130 of 161) with videos related to

Sort By:
Pageof 17
Antimicrobial Agents and Chemotherapy|January 29, 2014
Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirinEisuke Murakami, Michio Imamura, C Nelson Hayes, et al.
The Journal of Infectious Diseases|February 28, 2022
Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAILYosuke Suehiro, Masataka Tsuge, Mio Kurihara, et al.
Journal of Hepatology|December 15, 2010
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric miceEiji Ohara, Nobuhiko Hiraga, Michio Imamura, et al.
Antiviral Therapy|June 2, 2018
Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot studyYumiko Tatsukawa, Masataka Tsuge, Yoshiiku Kawakami, et al.
Antiviral Therapy|January 12, 2019
Correction: Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot studyYumiko Tatsukawa, Masataka Tsuge, Yoshiiku Kawakami, et al.
Biochemical and Biophysical Research Communications|October 22, 2013
A novel TK-NOG based humanized mouse model for the study of HBV and HCV infectionsKeiichi Kosaka, Nobuhiko Hiraga, Michio Imamura, et al.
Journal of Gastroenterology|March 5, 2016
Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infectionMasataka Tsuge, Nobuhiko Hiraga, Takuro Uchida, et al.
Journal of Gastroenterology and Hepatology|December 20, 2021
Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver diseaseYutaro Ogawa, Takashi Nakahara, Masafumi Ono, et al.
Journal of Gastroenterology|September 16, 2016
Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis CReona Morio, Michio Imamura, Yoshiiku Kawakami, et al.
Hepatology (Baltimore, Md.)|March 10, 2023
HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric miceTakuro Uchida, Michio Imamura, C Nelson Hayes, et al.
Pageof 17